In brief
In a major health initiative, Nigeria, the country with the highest malaria death toll globally, has begun administering the R21/Matrix-M malaria vaccine to children aged five to 15 months. The launch of the vaccine marks a pivotal development in the nation, which accounted for 31% of malaria deaths in 2022, translating to a staggering loss of 580,000 lives across Africa that year. The country’s health officials aim to mitigate malaria's devastating impact, particularly on children and pregnant women, who remain the most affected demographics.
With an estimated 75% effectiveness, the vaccine is being rolled out in Bayelsa and Kebbi—two of Nigeria's most malaria-ridden states—before expanding to the rest of the country by next year. During the launch in Bayelsa, local mother Happiness Idia-Wilson expressed her optimism for her son’s future health, emphasizing the role of community awareness, stating, "I will tell mothers, and I will invite people [to be vaccinated]."Experts stress the necessity of combining vaccination efforts with other preventive strategies such as mosquito nets and insecticides. Dr. Walter Mulombo, WHO’s representative in Nigeria, expressed hopes that the vaccine will significantly reduce malaria cases. The Nigerian government has identified a substantial economic burden linked to the disease, estimating yearly losses of $1.1 billion due to decreased productivity and healthcare costs resulting from malaria.Developed by the Jenner Institute at Oxford University, the R21/Matrix-M vaccine follows a regimen of three doses, administered four weeks apart, plus a booster after one year. Earlier in 2023, neighboring countries like Ivory Coast and the Democratic Republic of Congo also began incorporating this vaccine into their public health strategies.While Nigeria was excluded from the WHO’s roll-out of the previously trialed RTS,S vaccine across 12 African nations, the introduction of R21/Matrix-M signifies a hopeful turn in the fight against malaria in Africa, as health campaigns are set to enhance local understanding and acceptance of the vaccine's benefits.
